Christina Liang

Christina Liang

Auto-generated profile, based on publicly available information

Christina Liang

Sydney Medical School, Faculty of Medicine and Health, Northern (Arabanoo) Precinct, University of Sydney, Camperdown, NSW, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Neurology
Verified
Journal Article
Open access
PDF file
RDRyan L. Davis
Ryan L. Davis
KKKishore Raj Kumar
Kishore Raj Kumar
CPClare Puttick
Clare Puttick
CLChristina Liang
Christina Liang
KAKate E. Ahmad
Kate E. Ahmad
CSCarolyn M. Sue
Carolyn M. Sue
Background and Objectives Mitochondrial diseases (MDs) are the commonest group of heritable metabolic disorders. Phenotypic diversity can make molecular diagnosis challenging, and causative genetic variants may reside in either mitochondrial or nuclear DNA. A single comprehensive genetic diagnostic test would be highly useful and transform the field. We applied whole-genome sequencing (WGS) to evaluate the variant detection rate and diagnostic capacity of this technology with a view to simplifying and improving the MD diagnostic pathway. Methods Adult patients presenting to a specialist MD clinic in Sydney, Australia, were recruited to the study if they satisfied clinical MD (Nijmegen) criteria. WGS was performed on blood DNA, followed by clinical genetic analysis for known pathogenic MD-associated variants and MD mimics. Results Of the 242 consecutive patients recruited, 62 participants had “definite,” 108 had “probable,” and 72 had “possible” MD classification by the Nijmegen criteria. Disease-causing variants were identified for 130 participants, regardless of the location of the causative genetic variants, giving an overall diagnostic rate of 53.7% (130 of 242). Identification of causative genetic variants informed precise treatment, restored reproductive confidence, and optimized clinical management of MD. Discussion Comprehensive bigenomic sequencing accurately detects causative genetic variants in affected MD patients, simplifying diagnosis, enabling early treatment, and informing the risk of genetic transmission.

8 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DYDennis Yeow
Dennis Yeow
ARAndre Lm Reis
Andre Lm Reis
ISIgor Stevanovski
Igor Stevanovski
NNNeysa Njo
Neysa Njo
LRLaura Ivete Rudaks
Laura Ivete Rudaks
IDIra W Deveson
Ira W Deveson
Inherited myopathies are a group of disorders with diverse and complex genetic aetiologies. The causative genetic variants vary widely in type, size and sequence context, encompassing small sequence variants and large structural variants in protein-coding genes, mitochondrial variants, repeat expansions, and more complex events, such as the chromosome 4 D4Z4 macrosatellite contraction and hypomethylation that causes facioscapulohumeral muscular dystrophy (FSHD). This poses a challenge for analysis with next generation sequencing and other molecular methods. This is further compounded by phenotypic variability between patients and phenotypic overlap of different forms of genetic myopathy. To accelerate myopathy research and improve diagnosis we have developed a targeted long-read sequencing assay and an integrated bioinformatics analysis framework that captures the full suite of genes, variants and epigenetic signatures currently implicated in all forms of inherited myopathy. Applying this to a cohort of 53 myopathy patients with and without previous genetic diagnoses, we demonstrate the analytical validity of our approach, as well as its improved accuracy and resolution compared to existing methods - especially for FSHD. Our LRS assay identified an array of new information about the genetic and epigenetic landscape of inherited myopathies and provided new diagnoses for 29% of patients who had remained undiagnosed following clinical genetic testing. In our cohort, FSHD and oculopharyngodistal myopathies were the most common new diagnoses that were missed or mis-diagnosed by standard clinical genetic testing. Our new method constitutes a single streamlined assay for comprehensive genetic and epigenetic characterisation of inherited myopathies.

30 March 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
IAIqra Aziz
Iqra Aziz
MDMark Davis
Mark Davis
CLChristina Liang
Christina Liang
An elderly man in his early 80s presented with a 6-month history of worsening lower limb weakness on a background of a longer-standing waddling gait. Examination revealed bilateral scapular winging, and weakness in his proximal and distal lower limbs. Electromyography showed widespread chronic partial denervation changes, while sensory and motor nerve conduction parameters were preserved. After little progression over the course of 18 months, motor neuron disease was deemed less likely. Genetic testing revealed BICD2-related spinal muscular atrophy with lower extremity dominance (SMALED2), a disease that is usually of earlier onset. He is the oldest patient in the literature to be diagnosed with SMALED2 while maintaining ambulation, suggesting the milder spectrum of BICD2-related disease.

19 February 2022 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
SWSarah Williams
Sarah Williams
CLChristina Liang
Christina Liang
AGAlexander Guminski
Alexander Guminski
GHGeorge Hruby
George Hruby
DCDavid Chan
David Chan
We report on a 79-year-old man diagnosed with localized Merkel cell carcinoma (MCC) who also had acetylcholine receptor antibody (Ach-R-Ab)-positive myasthenia gravis (MG) controlled on prednisolone, mycophenolate and intravenous immunoglobulin (IVIG). His MCC was initially treated with radiation, followed by chemotherapy on metastatic recurrence. Chemotherapy initially stabilized the disease, but he experienced significant fatigue and his disease progressed within 3 months. After careful consideration of the risk of a myasthenic crisis, he was commenced on avelumab. He had initial partial response, though he ultimately developed progressive disease which led to a decision for best supportive care at 10 months post starting immunotherapy. Importantly, as per spirometry, his MG remained stable throughout immunotherapy. We present the current case to demonstrate that MG should not be viewed as an absolute contraindication to immunotherapy in scenarios where there are limited alternate therapeutic options.

29 June 2026 in medRxiv
Verified
Preprint
Open access
EWEloise Watson
Eloise Watson
GQGordon Qian
Gordon Qian
SRShyamsundar Ravishankar
Shyamsundar Ravishankar
MHMatthew Hobbs
Matthew Hobbs
JCJoseph Copty
Joseph Copty
CSCarolyn M. Sue
Carolyn M. Sue
Mitochondrial diseases (MDs) are clinically heterogeneous rendering ascertainment challenging. Estimates of pathogenic mitochondrial DNA (mtDNA) variants in the population range from 1 in 200 to 1 in 4,000 individuals. Inclusion of mtDNA sequencing in genomic databases facilitates comprehensive estimation of mtDNA variation. However, interpretation of low heteroplasmy variation is complex, due in part to misalignment of nuclear mitochondrial DNA transcripts (NUMTs), whilst conservative heteroplasmy thresholds likely omit relevant variation. Cumulative burden of mtDNA variation contributes to aging and neurodegeneration, and recent characterisation of mitochondrial genome constraint allows quantitation of this burden. We analysed whole genome sequencing of blood DNA from 3,500 healthy older individuals in the Medical Genome Reference Bank using mity , considering pathogenic mtDNA variants ≥1% heteroplasmy. We identified 34 distinct pathogenic mtDNA variants in 62 individuals, giving a combined population allele frequency of 1.77% (95% CI 1.36-2.27) or 1 in 56 individuals. We evaluated inclusion of false positive (FP) calls due to two common NUMTs, which accounted for up to 16% of variants. Increasing heteroplasmy thresholding to eliminate all NUMT-FPs also eliminated much of the total variation, including pathogenic variants. We propose a sample-specific, scaled heteroplasmy threshold to maximise variant retention and mitigate NUMT-FPs. Finally, we characterised measures of mitochondrial constraint in this healthy older cohort, observing an association between variant burden and summed constraint, whilst mean constraint was higher in pathogenic variant carriers. These findings suggest pathogenic mtDNA variation is more common in the population than is currently appreciated. Findings are comparable to larger genomic databases when heteroplasmy thresholding is adjusted, and support earlier population-based estimates. Incorporation of low heteroplasmy variation is relevant, but interpretation is nuanced, and optimising variant retention requires consideration of NUMT-FP rates.

18 May 2026 in medRxiv
Verified
Preprint
Open access
EWEloise C Watson
Eloise C Watson
SRShyamsundar Ravishankar
Shyamsundar Ravishankar
MHMatthew Hobbs
Matthew Hobbs
JCJoseph Copty
Joseph Copty
CYChenglong Yu
Chenglong Yu
CSCarolyn M Sue
Carolyn M Sue
Mitochondrial diseases (MDs) are genetically and phenotypically diverse and can be difficult to diagnose. Prevalence estimates derive largely from diagnosed cases and may underestimate population MD risk. Population-based studies are limited in scope and number but indicate MD variants are common. As genomic sequencing advances have made comprehensive population-based evaluation feasible, we sought to evaluate nuclear MD variation in a population cohort to understand variant prevalence and differences in MD risk estimates We identified disease-associated nuclear gene variants in 270 nuclear MD genes across 2,845 healthy older individuals in the Medical Genome Reference Bank. From Pathogenic or Likely Pathogenic Variants (PLPVs) we estimated autosomal recessive (AR) and autosomal dominant (AD) MD risk for individual genes and all nuclear variant-associated MDs. We identified 554 PLPV alleles representing 357 unique variants in 145 genes. Combined AR MD risk was estimated at 25.8 per 100,000 (95% CI 18.7 to 32.9), or 1 in 3,880 individuals. SPG7 (12.65 per 100,000; 95% CI 7.52-20.6) and POLG (4.23 per 100,000; 95% CI 2.10-8.01) contributed the greatest single gene AR MD risks and OPA1 variants posed the greatest AD MD risk. We observed a high rate of MD-associated nuclear gene variation in this healthy older cohort. The estimated lifetime AR MD risk was higher than commonly quoted prevalence estimates for all MDs, and the presence of common AD variants suggests variant penetrance may be lower than previously understood. These data help contextualise population MD risk and may inform clinical counselling and care.